Welcome to our dedicated page for HYPERFINE SEC filings (Ticker: HYPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hyperfine, Inc. filings document a Nasdaq-listed medical device company built around the Swoop® portable MR brain imaging system and related Optive AI™ software. Its Form 8-K reports cover operating results, business updates, preliminary unaudited financial information, investor presentations, and material definitive agreements, including a senior secured term loan facility used for working capital and general corporate purposes.
Proxy materials describe annual meeting matters, governance procedures, and shareholder voting. The filing record also identifies HYPR Class A common stock registered on Nasdaq and provides capital-structure and corporate-governance disclosures tied to commercialization of portable brain MRI.
Hyperfine, Inc. reported strong first quarter 2026 growth while remaining unprofitable. Revenue reached $3.90 million, up 83% from $2.14 million a year earlier, driven by sales of 10 Swoop® systems versus six in the prior-year quarter. Gross profit rose to $1.98 million, and gross margin improved to 51% from 41%.
Operating expenses declined slightly, with research and development down to $3.85 million from $5.04 million. Net loss narrowed to $8.62 million, or $0.09 per share, from $9.42 million, or $0.12 per share. Cash, cash equivalents and restricted cash increased to $41.28 million, supported by a $15.0 million debt financing that extends the expected cash runway into 2028. Management reaffirmed 2026 guidance for revenue of about $20–$22 million and cash burn of $26–$28 million.
Hyperfine, Inc. calls a virtual-only 2026 annual stockholder meeting on May 21, 2026 at 10:00 a.m. Eastern Time. Stockholders of record as of March 25, 2026 may vote Class A and high‑vote Class B shares via www.virtualshareholdermeeting.com/HYPR2026 using a 16‑digit control number.
Stockholders will elect five directors and vote on ratifying Grant Thornton LLP as independent auditor for the year ending December 31, 2026. Founder Jonathan Rothberg beneficially owns all 15,055,288 Class B shares, giving him majority voting control, so the company qualifies as a Nasdaq “controlled company.”
The proxy describes Hyperfine’s AI‑powered, portable Swoop MRI platform, recent FDA, CE Mark, UKCA and India regulatory clearances, and international expansion efforts. It also details executive and director compensation, equity plans, board committees, and an executive severance plan aligned with change‑in‑control situations.
HALE BRETT reported acquisition or exercise transactions in this Form 4 filing.
Hyperfine, Inc. reported that its CFO and CAO, Brett Hale, received an equity compensation grant of 330,000 restricted stock units (RSUs) of Class A common stock. The RSUs have no cash purchase price and represent the right to receive one share per unit upon vesting.
The award vests 25% on March 23, 2027, with the remaining RSUs vesting in equal quarterly installments over the following three years, subject to his continued service. After this grant, Hale beneficially owns 605,812 shares of Class A common stock, including these RSUs.
TEISSEYRE THOMAS reported acquisition or exercise transactions in this Form 4 filing.
Hyperfine, Inc. reported that Chief Operating Officer Dr. Thomas Teisseyre received an equity compensation grant of 330,000 shares of Class A Common Stock in the form of restricted stock units (RSUs). These RSUs carry no purchase price and increase his direct holdings to 684,648 shares.
The RSUs vest 25% on March 23, 2027, with the remaining 75% vesting in equal quarterly installments over the following three years, conditioned on his continued service. This structure is designed to retain the executive and align his incentives with long‑term company performance.
Hyperfine, Inc. reported that President and CEO Maria Sainz received a grant of 750,000 restricted stock units (RSUs) of Class A common stock at no cash cost. Each RSU converts into one share as it vests, serving as stock-based compensation rather than an open-market purchase.
The RSUs vest 25% on March 23, 2027, with the rest vesting in equal quarterly installments over the following three years, conditioned on her continued service. After this award and recent vesting activity, she directly holds 789,586 shares, including 19,586 shares from a 2021 RSU vesting and 20,000 purchased shares.
Hyperfine, Inc. Chief Operating Officer Thomas Teisseyre reported an open-market sale of 24,188 shares of Class A common stock at $1.21 per share. According to the footnote, the sale was made solely to cover tax withholding obligations tied to the vesting of restricted stock units under a “sell to cover” provision. After this transaction, he directly holds 354,648 shares, indicating it is a routine tax-related disposition rather than a discretionary change in his overall ownership stake.
Hyperfine, Inc. CFO and CAO Brett Hale reported an open-market sale of 24,188 shares of Class A common stock at an average price of $1.21 per share. According to the footnote, these shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, and Hale now holds 275,812 shares directly.
Hyperfine, Inc. reports on its business as an early-stage health technology company focused on AI-powered, ultra-low-field portable brain MRI. Its flagship Swoop® Portable MR Imaging® System brings bedside brain imaging to hospitals and neurology offices using a 0.064T permanent magnet and Optive AI™ software.
The company targets more than $16 billion in potential U.S. device placements, selling systems with recurring software, service and support agreements. It emphasizes multiple FDA 510(k) clearances, CE Mark, UKCA Mark and Indian approval, a portfolio of 197 issued patents and 160 pending applications, and a strategy spanning U.S. hospitals, neurology offices and international distributors.
Hyperfine highlights significant risks, including a history of net losses, ongoing capital needs, dependence on market adoption, single-source manufacturing for key components, extensive healthcare regulation, cybersecurity and data-privacy exposure, controlled-company governance, and concentrated voting power with founder Jonathan M. Rothberg, Ph.D.
Hyperfine, Inc. entered into a senior secured term loan agreement with Horizon Technology Finance for up to $40.0 million. The company drew $15.0 million at closing, with another $25.0 million available through December 31, 2027 if conditions are met.
The loan bears interest at the prime rate plus 4.25%, with a prime floor of 6.50% and a minimum overall rate of 10.75%, and initially requires 48 months of interest-only payments. Hyperfine paid a $400,000 commitment fee and must make a final payment equal to 5.0% of the aggregate original principal at payoff.
As part of the financing, Hyperfine issued warrants to Horizon for up to 562,500 shares of Class A common stock as Initial Warrants and up to 520,835 shares as Additional Warrants, each with a $1.20 exercise price. The Initial Warrants are immediately exercisable, while the Additional Warrants become exercisable only if further loan tranches are funded. The loan is guaranteed by two wholly owned subsidiaries and secured by substantially all company assets, subject to customary exclusions, and includes standard covenants and events of default.